Treatment Response Imaging in Prostate Cancer

被引：0

作者：

Swiha, Mina ^{[1
,2
]}

Gafita, Andrei ^{[3
]}

Nguyen, Andrew ^{[1
,4
]}

Emmett, Louise ^{[1
,4
,5
]}

机构：

[1] St Vincents Hosp, Dept Theranost & Nucl Med, Sydney, Australia

[2] Univ Western Ontario, Dept Med Imaging, Nucl Med Div, London, ON, Canada

[3] Johns Hopkins Med, Russell H Morgan Dept Radiol & Radiol Sci, Nucl Med & Mol Imaging Div, Baltimore, MD USA

[4] Univ New South Wales, St Vincents Clin Sch, Sydney, Australia

[5] Garvan Inst Med Res, Sydney, Australia

来源：

PET CLINICS | 2024年 / 19卷 / 03期

关键词：

Prostate cancer; PSMA-PET; PSMA-SPECT; 177Lu-PSMA; Treatment response; PSMA-PET; RADIOLIGAND THERAPY; OPEN-LABEL; CRITERIA; MITOXANTRONE; CABAZITAXEL; TOMOGRAPHY; PREDNISONE; RECIST;

D O I：

10.1016/j.cpet.2024.03.009

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Posttherapy imaging is a crucial tool for response assessment to both local and systemic therapies in early stage and late -stage PCa, with conventional imaging (diagnostic CT and bone scan) currently remaining standard of care. PSMA PET/ CT, an innovative molecular imaging tool, has shown potential in response assessment in PCa, but more research is required to validate it for clinical use. PSMA SPECT/CT is a potential costeffective alternative to PSMA PET/CT in assessment of response to PSMA-targeted radionuclide therapy that also warrants further evaluation. 18 F- FDG-PET/CT have a complementary role in nonPSMA-avid disease.

引用

页码：417 / 430

页数：14

共 51 条

[1] Increased PSMA Expression in 177Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide A Potential Game-Changer [J].

Aggarwal, Piyush ;

Kaur, Komalpreet ;

Sood, Ashwani ;

Periasamy, Kannan ;

Nagi, Shreya ;

Mittal, Bhagwant Rai .

CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) :411-413

[2] PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature [J].

Alongi, Pierpaolo ;

Laudicella, Riccardo ;

Lanzafame, Helena ;

Farolfi, Andrea ;

Mapelli, Paola ;

Picchio, Maria ;

Burger, Irene A. ;

Iagaru, Andrei ;

Minutoli, Fabio ;

Evangelista, Laura .

CANCERS, 2022, 14 (07)

[3] Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer [J].

Anton, Angelyn ;

Kamel Hasan, Olfat ;

Ballok, Zita ;

Bowden, Patrick ;

Costello, Anthony J. ;

Harewood, Laurence ;

Corcoran, Niall M. ;

Dundee, Phil ;

Peters, Justin S. ;

Lawrentschuk, Nathan ;

Troy, Andrew ;

Webb, David ;

Chan, Yee ;

See, Andrew ;

Siva, Shankar ;

Murphy, Declan ;

Hofman, Michael S. ;

Tran, Ben .

BJU INTERNATIONAL, 2020, 126 (04) :433-435

[4]

Baumann R, 2018, STRAHLENTHER ONKOL, V194, P318, DOI 10.1007/s00066-017-1239-1

[5] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial [J].

Buteau, James P. ;

Martin, Andrew J. ;

Emmett, Louise ;

Iravani, Amir ;

Sandhu, Shahneen ;

Joshua, Anthony M. ;

Francis, Roslyn J. ;

Zhang, Alison Y. ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Azad, Arun A. ;

McJannett, Margaret M. ;

Stockler, Martin R. ;

Williams, Scott G. ;

Davis, Ian ;

Hofman, Michael S. .

LANCET ONCOLOGY, 2022, 23 (11) :1389-1397

[6] Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence [J].

Calais, Jeremie ;

Fendler, Wolfgang P. ;

Herrmann, Ken ;

Eiber, Matthias ;

Ceci, Francesco .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) :789-794

[7]

Caromile LA, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1321168

[8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[9] 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer [J].

de Jong, Anouk C. ;

Segbers, Marcel ;

Ling, Sui Wai ;

Graven, Laura H. ;

Mehra, Niven ;

Hamberg, Paul ;

Brabander, Tessa ;

de Wit, Ronald ;

van der Veldt, Astrid A. M. .

JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (10) :1556-1562

[10] Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice [J].

Denis, Chloe S. ;

Cousin, Francois ;

De Laere, Bram ;

Hustinx, Roland ;

Sautois, Brieuc R. ;

Withofs, Nadia .

JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) :1815-1821

← 1 2 3 4 5 6 →